Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trialLaure Gossec, Laura C Coates, Dafna D Gladman, Jacob A Aelion, Jitendra Vasandani, Andreas Pinter, Joseph F Merola, Arthur Kavanaugh, Jyotsna Reddy, Rebecca Wang, Michele Brunori, Yuri Klyachkin, Cynthia Deignan, Philip J Mease
20 August 2024
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritisAndreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Jan W Schoones, Laure Gossec
19 March 2024
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort studySofia Exarchou, Daniela Di Giuseppe, Eva Klingberg, Valgerdur Sigurdardottir, Sara Wedrén, Ulf Lindström, Carl Turesson, Lennart T H Jacobsson, Johan Askling, Johan K Wallman
1 December 2023
Specific descriptions of axial involvement are associated with radiographic damage development after 2 years in psoriatic arthritis patientsManouk de Hooge, Alla Ischenko, Serge Steinfeld, Adrien Nzeusseu, Dirk Elewaut, Rik Lories, Filip Van den Bosch, Kurt De Vlam
2 November 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert BM Landewé
11 September 2023
EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritisAlen Zabotti, Gabriele De Marco, Laure Gossec, Xenofon Baraliakos, Daniel Aletaha, Annamaria Iagnocco, Paolo Gisondi, Peter V Balint, Heidi Bertheussen, Wolf-Henning Boehncke, Nemanja S Damjanov, Maarten de Wit, Enzo Errichetti, Helena Marzo-Ortega, Mikhail ProtopopovSee the full list of authors
9 June 2023
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registriesBente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C Nordström, Bjorn Gudbjornsson, Merete Lund Hetland, Johan Askling, Gerdur Grondal, Tuulikki Sokka, Sella A Provan, Brigitte Michelsen, Eirik Klami Kristianslund, Lene Dreyer, Thorvardur Jon Love, Ulf Lindström
22 February 2023
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Mohamed Sharaf, Elke Theander, Josef S Smolen
13 December 2022
Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skinAlba Boix-Amorós, Michelle H Badri, Julia Manasson, Rebecca B Blank, Rebecca H Haberman, Andrea L Neimann, Parvathy V Girija, Anthony Jimenez Hernandez, Adriana Heguy, Sergei B Koralov, Richard Bonneau, Jose C Clemente, Jose U Scher
12 December 2022
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trialCelia AJ Michielsens, Nathan den Broeder, Frank HJ van den Hoogen, Elien AM Mahler, Steven Teerenstra, Désirée van der Heijde, Lise M Verhoef, Alfons A den Broeder
14 June 2022